Eli Lilly's diabetes drug Mounjaro is losing market share in India due to the entry of cheaper generic GLP-1 competitors, causing its sales to fall from $14.6 million in February to $12.3 million in March. Semaglutide generics have increased their market share to 33%, while Mounjaro's share declined to 64%. Despite this, Mounjaro remains the market leader. Meanwhile, Eli Lilly's recent FDA approval of Foundayo, an oral GLP-1 pill for obesity, aims to strengthen its position against competitors like Novo Nordisk in the growing GLP-1 treatment market.
Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, gaining access to experimental drugs targeting mental health conditions like treatment-resistant depression. AtaiBeckley's lead drug, a DMT-based nasal sp...
Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...
